T-cell-engaging B7-H4/CD3 bispecific Fab-scFv antibody targeting human breast cancer

被引：0
|
作者：
Iizuka, Akira [1 ]
Ashizawa, Tadashi [1 ]
Ohshima, Keiichi [2 ]
Kusuhara, Masatoshi [3 ]
Yamaguchi, Ken [4 ]
Akiyama, Yasuto [1 ]
机构：
[1] Shizuoka Canc Ctr, Res Inst, Dept Immunother, Nagaizumi, Shizuoka, Japan
[2] Shizuoka Canc Ctr, Res Inst, Med Genet Div, Nagaizumi, Shizuoka, Japan
[3] Shizuoka Canc Ctr, Res Inst, Reg Resources Div, Nagaizumi, Shizuoka, Japan
[4] Shizuoka Canc Ctr, Nagaizumi, Shizuoka, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-1143
引用
收藏
页码：413 / 413
页数：1
相关论文
共 50 条
  • [41] Early Pharmacodynamic Changes in T-Cell Activation, Proliferation, and Cytokine Production Confirm the Mode of Action of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
    Nakamura, Rin
    Lear, Sean
    Wilson, Deanna
    Koeppen, Hartmut
    Vaze, Anjali
    Trudel, Suzanne
    Spencer, Andrew
    Harrison, Simon J.
    Cohen, Adam D.
    Fine, Bernard M.
    Li, Mengsong
    Cooper, James
    Sumiyoshi, Teiko
    BLOOD, 2020, 136
  • [42] Suppression of human T-cell responses to β-cells by activation of B7-H4 pathway
    Ou, Dawei
    Wangj, Xiaojie
    Metzger, Daniel L.
    Ao, Ziliang
    Pozzilli, Paolo
    James, Roger F. L.
    Chen, Lieping
    Warnock, Garth L.
    CELL TRANSPLANTATION, 2006, 15 (05) : 399 - 410
  • [43] GLP toxicology study of a fully-human T cell redirecting CD3:EGFRvIII binding immunotherapeutic bispecific antibody
    Gedeon, Patrick C.
    Streicker, Michael A.
    Schaller, Teilo H.
    Archer, Gary E.
    Jokinen, Micheal P.
    Sampson, John H.
    PLOS ONE, 2020, 15 (07):
  • [44] A bispecific T-cell engager antibody (BiTE) against TAG-72/CD3 for targeted cancer immunotherapy
    Khambati, Fatema
    Soliman, Hatem
    CANCER RESEARCH, 2019, 79 (13)
  • [45] Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment
    Zheng, Wei-Wei
    Zhou, Hang
    Li, Ping
    Ye, Shi-Guang
    Abudureheman, Tuersunayi
    Yang, Li-Ting
    Qing, Kai
    Liang, Ai-Bin
    Chen, Kai-Ming
    Duan, Cai-Wen
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (11) : 3739 - 3753
  • [46] Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment
    Wei-Wei Zheng
    Hang Zhou
    Ping Li
    Shi-Guang Ye
    Tuersunayi Abudureheman
    Li-Ting Yang
    Kai Qing
    Ai-Bin Liang
    Kai-Ming Chen
    Cai-Wen Duan
    Cancer Immunology, Immunotherapy, 2023, 72 : 3739 - 3753
  • [47] Effect of modulation of CD3 binding in a PSMAxCD3 T-cell engaging bispecific antibody on maintenance of efficient tumor cell kill and cytokine release.
    Buelow, Ben
    Dang, Kevin
    Dalvi, Pranjali
    Li, Yuping
    Cheung, Alexander
    Rancan, Chiara
    Sankaran, Preethi
    Duy Pham
    Harris, Katherine
    Davison, Laura
    Balasubramani, Aarti
    Clarke, Starlynn
    Starzinski, Alec
    Fong, Lawrence
    Iyer, Suhasini
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] A Bispecific Antibody Targeting CD117 and CD3 Enables T Cell Mediated Killing of CD117-Expressing Healthy and Malignant Hematopoietic Cells
    Kiefer, Jonathan D.
    Myburgh, Renier
    Russkamp, Norman F.
    Volta, Laura
    Guggisberg, Adrian
    Abdelmotaleb, Omar
    Mock, Jacqueline
    Neri, Dario
    Manz, Markus G.
    BLOOD, 2021, 138
  • [49] Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo
    Juan Ma
    Tengfei Shang
    Pan Ma
    Xin Sun
    Jin Zhao
    Ximing Sun
    Man Zhang
    Investigational New Drugs, 2019, 37 : 1036 - 1043
  • [50] Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells
    Supimon, Kamonlapat
    Sangsuwannukul, Thanich
    Luangwattananun, Piriya
    Yenchitsomanus, Pa-thai
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 143
12345